about
Performance Comparison of Three Rapid Tests for the Diagnosis of Drug-Resistant TuberculosisThe Global Consortium for Drug-resistant Tuberculosis Diagnostics (GCDD): design of a multi-site, head-to-head study of three rapid tests to detect extensively drug-resistant tuberculosisPredicting extensively drug-resistant Mycobacterium tuberculosis phenotypes with genetic mutationsSecond-line drug susceptibility breakpoints for Mycobacterium tuberculosis using the MODS assayEvaluation of pyrosequencing for detecting extensively drug-resistant Mycobacterium tuberculosis among clinical isolates from four high-burden countriesMultidrug-resistant tuberculosis in Europe, 2010-2011Combined antigen-specific interferon-γ and interleukin-2 release assay (FluoroSpot) for the diagnosis of Mycobacterium tuberculosis infection.Evolutionary history and global spread of the Mycobacterium tuberculosis Beijing lineage.Phenotypic and genotypic diversity in a multinational sample of drug-resistant Mycobacterium tuberculosis isolates.Novel katG mutations causing isoniazid resistance in clinical M. tuberculosis isolates.Shedding light on the performance of a pyrosequencing assay for drug-resistant tuberculosis diagnosis.Predicting differential rifamycin resistance in clinical Mycobacterium tuberculosis isolates by specific rpoB mutations.MTBDRplus and MTBDRsl Assays: Absence of Wild-Type Probe Hybridization and Implications for Detection of Drug-Resistant Tuberculosis.A performance evaluation of MTBDRplus version 2 for the diagnosis of multidrug-resistant tuberculosis.Risk factors and timing of default from treatment for non-multidrug-resistant tuberculosis in MoldovaFrequency and Distribution of Tuberculosis Resistance-Associated Mutations between Mumbai, Moldova, and Eastern CapeRapid Drug Susceptibility Testing of Drug-Resistant Mycobacterium tuberculosis Isolates Directly from Clinical Samples by Use of Amplicon Sequencing: a Proof-of-Concept Study.Armed conflict and population displacement as drivers of the evolution and dispersal of Mycobacterium tuberculosis.Geographical differences associated with single-nucleotide polymorphisms (SNPs) in nine gene targets among resistant clinical isolates of Mycobacterium tuberculosis.High risk and rapid appearance of multidrug resistance during tuberculosis treatment in Moldova.The TB Portals: an Open-Access, Web-Based Platform for Global Drug-Resistant-Tuberculosis Data Sharing and Analysis.Tuberculosis Treatment Outcomes in Europe: Based on Treatment Completion, Not Cure.MDR-TB in Eastern Europe in the era of the TB elimination action framework.Nosocomial transmission of multidrug-resistant tuberculosis.Treatment outcomes of MDR-TB and HIV co-infection in Europe.Lack of evidence of isoniazid efficacy for the treatment of MDR/XDR-TB in the presence of the katG 315T mutation.High-dose isoniazid in the shorter-course multidrug-resistant tuberculosis regimen in the Republic of Moldova.Cost analysis of rapid diagnostics for drug-resistant tuberculosis.Clinical Management of Multidrug-resistant Tuberculosis in 16 European Countries.Treatment Outcomes in Multidrug-Resistant Tuberculosis.Failing treatment of multidrug-resistant tuberculosis: a matter of definitionA retrospective genomic analysis of drug-resistant strains of M. tuberculosis in a high-burden setting, with an emphasis on comparative diagnostics and reactivation and reinfection statusBuilding a tuberculosis-free world: The Lancet Commission on tuberculosisAssessing tuberculosis control priorities in high-burden settings: a modelling approach
P50
Q28387375-16F5D62C-D218-4604-8AD3-E8C7033180C9Q28397729-72DF05E1-FAA2-4FFA-8FAE-599FDA02EFF8Q28397752-DE2688F8-896D-4B8F-AB34-DC8849DA5312Q34604407-3488BFCB-06F7-4250-BCDA-EC9BFFFC9D65Q34922635-638F99F0-1067-4514-976B-26B514993231Q35130346-83D53EA3-0410-4B47-9DC3-889D95C0DFE4Q35192333-E4B06E53-42D4-4EDD-AAA3-515795D01DB0Q35544538-BFEBEC85-D546-47DF-82ED-358932B698C8Q35828310-DFC6AD4C-8B73-4238-A1B4-CADD6F259EB9Q35909558-37B0553F-2064-4CE5-A842-C007CD1B71BFQ36117376-CD84B484-DA39-44CB-ABCC-FF5E916DC7DEQ36169719-206AEB37-88EB-4E1E-B79E-E532F84B23E8Q36734934-F6B403F7-8B80-4784-B1B4-DA5AC519BAE6Q36855346-0D53DD58-B391-486F-ABD9-17D8B14F85E7Q37010202-0E59F00A-C0A8-425A-BDA5-91CEE4DD0031Q37023127-EF1FECE5-E9E5-4547-BA12-267D21A553DCQ37132034-190559FB-F5E2-4D07-BF15-190865E21417Q37473631-E4445992-C378-4700-832A-2B5D59FBCD11Q37713793-C0D61489-6598-464D-804A-C0C47CE4705BQ37733149-205AAD9E-9853-45DD-8606-70A30BCBAA1BQ40048063-74326ADE-0035-4C22-BBBC-E636978DE0A8Q40286070-F154D0AC-CED4-4C91-8CFD-16EC2AAAAA29Q40347076-A946D11B-FCC9-4778-90AB-D7EA36C703D6Q40891953-4ACF1251-D00F-46F9-B69A-B2C2800179B1Q47868204-E7A79621-058A-4071-A442-A30D934D431CQ48196619-0104EFE9-43E0-4055-87F7-510908D98182Q48196626-85EFD271-8419-4FEE-8873-C2F2CC42121CQ51736589-E603A0F9-B718-433C-9F28-39FD6F10DACDQ53704318-A9A370D0-6D66-4D06-8E36-205838E30C3EQ53769778-9E244ECF-5138-4CF1-A0B7-D1B2EE18386CQ91830345-B9D5E5B7-3F71-4A35-A1EE-81FE3C0E9407Q92475605-BFE8865D-8E49-4B2B-BF99-E3A298D74107Q92572142-58C9B81F-88EB-45D2-9D2E-4D2643919B1CQ92573258-26BCC223-4C57-4904-8E76-A8E84549431A
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Valeru Crudu
@en
Valeru Crudu
@nl
type
label
Valeru Crudu
@en
Valeru Crudu
@nl
prefLabel
Valeru Crudu
@en
Valeru Crudu
@nl
P31
P496
0000-0001-5059-8002